Skip to content

L · 0R29.L · MEDICAL - DEVICES

Intuitive Surgical, Inc. (0R29.L) intrinsic value and stock valuation

$405.33as of 2026-11-21 · Mkt cap 149.27B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Intuitive Surgical, Inc. DCF and intrinsic value

InvestorsCraft values 0R29.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0R29.L’s statements →

Intuitive Surgical, Inc. Graham Number

Graham Number: $95.14d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Sunnyvale, CA 94086-5304 intuitive.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$10.1B+18.2% 5y CAGRd
20122025
Net income
$2.86B+21.9% 5y CAGRd
20122025
Free cash flow
$2.49B+16.9% 5y CAGRd
20122025
Total equity
$17.9B+13% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$10.1B$8.35B$7.12B$6.22B$5.71B
Operating income$2.95B$2.35B$1.77B$1.58B$1.82B
Net income$2.86B$2.32B$1.8B$1.32B$1.7B
EPSd$7.87M$6.42M$5.03M$3.65M$4.66M
Operating cash flow$3.03B$2.42B$1.81B$1.49B$2.09B
Capital expenditure-$-539.8M-$-1.11B-$-1.06B-$-532.4M-$-353.5M
Free cash flow$2.49B$1.3B$749.6M$958.4M$1.74B
Total assets$20.6B$18.8B$15.4B$13B$13.6B
Total debt$170.9M$146M$89.8M$93.8M$87M
Net debt-$-3.2B-$-1.88B-$-2.66B-$-1.49B-$-1.2B
Total equity$17.9B$16.5B$13.4B$11.1B$12B
Cash and short-term investments$5.93B$4.01B$5.22B$4.12B$4.2B
Income statement
20252024202320222021
Revenue$10.1B$8.35B$7.12B$6.22B$5.71B
Cost of revenue$3.41B$2.72B$2.39B$2.03B$1.77B
Gross profit$6.66B$5.63B$4.73B$4.19B$3.94B
Research and development expenses$1.31B$1.15B$998.8M$876.3M$659.9M
Selling, general and administrative expenses$2.39B$2.14B$1.96B$1.73B$1.46B
Other expenses$13.2M$0.00$0.00$0.00$0.00
Operating expenses$3.71B$3.29B$2.96B$2.61B$2.12B
Cost and expenses$7.12B-$-6B$5.36B$4.65B$3.89B
Interest income$365.9M$0.00$0.00$106M$80.8M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$625.1M$455.7M$402.2M$380.4M$317M
Ebitda$3.57B$3.13B$2.17B$1.99B$2.14B
Operating income$2.95B$2.35B$1.77B$1.58B$1.82B
Total other income/expenses, net$365.9M$324.9M$192.1M$29.7M$69.3M
Income before tax$3.31B$2.67B$1.96B$1.61B$1.89B
Income tax expense$434.8M$336.3M$141.6M$262.4M$162.2M
Net income$2.86B$2.32B$1.8B$1.32B$1.7B
Weighted average shares outstanding$356.9M$355.2M$351.2M$355.7M$356.1M
Weighted average diluted shares outstanding$362.7M$362M$357.4M$362M$365.8M
Balance sheet
20252024202320222021
Cash and short-term investments$5.93B$4.01B$5.22B$4.12B$4.2B
Net receivables$1.63B$1.36B$1.27B$1.07B$893M
Inventory$1.84B$1.49B$1.22B$893.2M$587.1M
Total current assets$9.78B$7.11B$7.89B$6.25B$5.84B
Property, plant and equipment, net$5.49B$4.78B$3.62B$2.46B$1.95B
Goodwill and intangible assets$381.4M$370.5M$387.8M$398.3M$414.1M
Long-term investments$3.3B$5.06B$2.19B$2.98B$4.69B
Total non-current assets$10.9B$11.7B$7.55B$6.72B$7.71B
Total assets$20.6B$18.8B$15.4B$13B$13.6B
Accounts payable$255.1M$193.4M$188.7M$147M$121.2M
Short-term debt$39M$33.5M$25.3M$24.2M$20.4M
Deferred revenue$506.7M$468.8M$0.00$397.3M$377.2M
Total current liabilities$2.01B$1.75B$1.66B$1.42B$1.15B
Long-term debt$131.9M$112.5M$64.5M$69.6M$66.6M
Deferred revenue, non-current$91.4M$54.1M$0.00$41M$36.8M
Total non-current liabilities$683.3M$563.7M$467.6M$439.3M$453.7M
Capital lease obligations$131.9M$112.5M$89.8M$93.8M$87M
Total liabilities$2.69B$2.31B$2.04B$1.86B$1.6B
Common stock$400K$400K$400K$400K$400K
Retained earnings$7.01B$6.8B$4.74B$3.5B$4.76B
Accumulated other comprehensive income (loss)$43.3M-$-51.3M-$-12.2M-$-162.5M-$-24.2M
Total equity$17.9B$16.5B$13.4B$11.1B$12B
Total investments$5.87B$7.05B$4.67B$5.52B$7.61B
Total debt$170.9M$146M$89.8M$93.8M$87M
Net debt-$-3.2B-$-1.88B-$-2.66B-$-1.49B-$-1.2B
Cash flow statement
20252024202320222021
Net income$2.86B$2.32B$1.8B$1.32B$1.7B
Depreciation and amortization$625.1M$455.7M$435.2M$380.4M$317M
Stock-based compensation$0.00$0.00$598.2M$516.5M$456.8M
Change in working capital-$-1.27B-$-919.3M-$-872.7M-$-619.1M-$-368.1M
Accounts receivable-$-301.7M-$-95.9M-$-186.3M-$-159.3M-$-142.3M
Inventory-$-1.06B-$-830M-$-712.5M-$-546.6M-$-256M
Accounts payable$57.9M-$-400K$41.7M$21.3M$36M
Net cash provided by operating activities$3.03B$2.42B$1.81B$1.49B$2.09B
Investments in property, plant and equipment-$-539.8M-$-1.11B-$-1.06B-$-532.4M-$-353.5M
Acquisitions, net$0.00-$-1M-$-8.9M-$-12.8M-$-8.7M
Net cash used for investing activities$665.8M-$-3.27B-$-360.1M$1.37B-$-2.46B
Common stock issued$350.3M$429.4M$0.00$233.8M$276.5M
Common stock repurchased-$-2.3B$0.00-$-581M-$-2.61B-$-211.6M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-2.36B$150.9M-$-287.6M-$-2.57B$43M
Net change in cash$1.34B$0.00$1.17B$290.3M-$-331.7M
Cash at end of period$3.37B$2.03B$2.77B$1.58B$1.29B
Operating cash flow$3.03B$2.42B$1.81B$1.49B$2.09B
Capital expenditure-$-539.8M-$-1.11B-$-1.06B-$-532.4M-$-353.5M
Free cash flow$2.49B$1.3B$749.6M$958.4M$1.74B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Intuitive Surgical, Inc.

        Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

        CEO
        David J. Rosa
        Employees
        15.64K
        Beta
        1.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Intuitive Surgical, Inc. (0R29.L)?

        InvestorsCraft does not currently publish an intrinsic value for 0R29.L. How the IC value is calculated.

        Is 0R29.L undervalued?

        InvestorsCraft does not publish an undervaluation signal for 0R29.L at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.